Back to homepage

Haematology and Oncology

Harnessing the immune system in the battle against breast cancer

Authors: Elizabeth S Nakasone MD, PhD, Sara A Hurvitz MD, Kelly E McCann MD, PhD

This article examines the major approaches to immunotherapy in breast cancers, both successes and failures, as well as new therapies on the horizon.

More

Approving cancer treatments based on endpoints other than overall survival: an analysis of historical data using the PACE Continuous Innovation Indicators™ (CII)

Authors: Neon Brooks, Mario Campone, Silvia Paddock, Scott Shortenhaus, David Grainger, Jacqueline Zummo, Samuel Thomas, Rose Li

This article examines the relationship between U.S. Food and Drug Administration (FDA) approval and the publication of OS evidence to understand better the risks and benefits of delaying approval until OS evidence is available.

More

Prognostic and predictive factors of eribulin efficacy in heavily pretreated patients affected by metastatic breast cancer: correlation with tumor biology and previous therapies

Authors: Sabrina Rossi, Alessandra Cassano, Antonia Strippoli, Giovanni Schinzari, Ettore D’Argento, Michele Basso, Carlo Barone

This retrospective study looks to find specific predictive criteria related to patient or tumor characteristics in order to select patients that might benefit the most from eribulin and define the correct treatment sequence.

More

Synchronous GISTs associated with multiple sporadic tumors: a case report

Authors: Danila Comandini, Azzurra Damiani, Alessandro Pastorino

The authors report a case of primary prostate and lung tumors associated with gastric and small bowel GISTs, unrelated to any known hereditary syndrome.

More

Long-term efficacy and safety of fourth-line multikinase inhibitor treatment with lenvatinib in a young papillary thyroid carcinoma patient

Authors: S. Morelli, E. Puxeddu

This article reports on the case of a young papillary thyroid cancer patient, pretreated with three other kinase inhibitors, who achieved a long-term clinical benefit from lenvatinib in the fourth-line setting.

More